BS_GYXSDZ56
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 59.13272010512483
- age_years
- 12.786
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.545
- INTERFERON_ALPHA_RESPONSE+0.539
- TNFA_SIGNALING_VIA_NFKB+0.531
- INFLAMMATORY_RESPONSE+0.513
- IL6_JAK_STAT3_SIGNALING+0.500
- ALLOGRAFT_REJECTION+0.492
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.463
- IL2_STAT5_SIGNALING+0.408
- COMPLEMENT+0.400
- APOPTOSIS+0.396
Top 10 suppressed
- E2F_TARGETS-0.473
- G2M_CHECKPOINT-0.425
- MYC_TARGETS_V1-0.349
- MYC_TARGETS_V2-0.261
- SPERMATOGENESIS-0.255
- DNA_REPAIR-0.182
- PANCREAS_BETA_CELLS-0.154
- MITOTIC_SPINDLE-0.102
- WNT_BETA_CATENIN_SIGNALING-0.002
- CHOLESTEROL_HOMEOSTASIS+0.013
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_V3REENH9 | pilocytic astrocytoma | — | 0.966 |
| 2 | BS_VW85Q4XJ | low-grade glioma | — | 0.960 |
| 3 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.955 |
| 4 | BS_V89HGTET | pilocytic astrocytoma | — | 0.947 |
| 5 | BS_MF9X3PKH | low-grade glioma | — | 0.945 |
| 6 | BS_NRPG5K4K | low-grade glioma | — | 0.944 |
| 7 | BS_HC5M8JTC | low-grade glioma | — | 0.944 |
| 8 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.936 |
| 9 | BS_X16PENSA | pilocytic astrocytoma | — | 0.935 |
| 10 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.934 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.545 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.539 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.531 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.513 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.492 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.463 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.408 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| APOPTOSIS | 0.396 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.394 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.376 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.362 | Inavolisib | — uncovered |
| COAGULATION | 0.359 | Binimetinib | — uncovered |
| MYOGENESIS | 0.355 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.328 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.324 | Inavolisib | — uncovered |
| HYPOXIA | 0.313 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.301 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.296 | Inavolisib | — uncovered |